The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Geng, Wei ^a   Ng, Kevin T P ^a   Sun, Chris K W ^a   Yau, Wing Lung ^a   Liu, Xiao Bing ^a   Cheng, Qiao ^a   Poon, Ronnie T P ^a   Lo, Chung Mau ^a   Man, Kwan ^a   Fan, Sheung Tat ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; FOCAL ADHESION KINASE 2; GAGE1 PROTEIN; LIPOCORTIN 5; MICROTUBULE ASSOCIATED PROTEIN 7; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN KINASE B; STAT1 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DNA MICROARRAY; DRUG MECHANISM; DRUG TOLERANCE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENETICS; LIVER TUMOR; METABOLISM; NUDE MOUSE; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

MUS MUSCULUS;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FOCAL ADHESION KINASE 2; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80655141609     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027362     Document Type: Article

References (50)

1. El-Serag HB, Rudolph KL, (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576.
2. Kerr SH, Kerr DJ, (2009) Novel treatments for hepatocellular cancer. Cancer Lett 286: 114-120.
3. Kawano Y, Sasaki A, Kai S, Endo Y, Iwaki K, et al. (2009) Prognosis of patients with intrahepatic recurrence after hepatic resection for hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol 35: 174-179.
4. Thomas M, (2009) Molecular targeted therapy for hepatocellular carcinoma. J Gastroenterol 44 (Suppl 19): 136-141.
5. Spangenberg HC, Thimme R, Blum HE, (2009) Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol.
6. Aravalli RN, Steer CJ, Cressman EN, (2008) Molecular mechanisms of hepatocellular carcinoma. Hepatology.
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
8. Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, et al. (2009) Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 14: 95-100.
9. Yau T, Chan P, Epstein R, Poon RT, (2009) Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 29: 10-17.
10. Zhao J, Guan JL, (2009) Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev 28: 35-49.
11. Golubovskaya VM, Kweh FA, Cance WG, (2009) Focal adhesion kinase and cancer. Histol Histopathol 24: 503-510.
12. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, et al. (2005) The role of focal-adhesion kinase in cancer- a new therapeutic opportunity. Nat Rev Cancer 5: 505-515.
13. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, et al. (2000) FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2: 249-256.
14. Sasaki H, Nagura K, Ishino M, Tobioka H, Kotani K, et al. (1995) Cloning and characterization of cell adhesion kinase beta, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. J Biol Chem 270: 21206-21219.
15. Avraham H, Park SY, Schinkmann K, Avraham S, (2000) RAFTK/Pyk2-mediated cellular signalling. Cell Signal 12: 123-133.
16. Iiizumi M, Bandyopadhyay S, Pai SK, Watabe M, Hirota S, et al. (2008) RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer. Cancer Res 68: 7613-7620.
17. Stanzione R, Picascia A, Chieffi P, Imbimbo C, Palmieri A, et al. (2001) Variations of proline-rich kinase Pyk2 expression correlate with prostate cancer progression. Lab Invest 81: 51-59.
18. Picascia A, Stanzione R, Chieffi P, Kisslinger A, Dikic I, et al. (2002) Proline-rich tyrosine kinase 2 regulates proliferation and differentiation of prostate cells. Mol Cell Endocrinol 186: 81-87.
19. Zhang S, Qiu X, Gu Y, Wang E, (2008) Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer. Lung Cancer 62: 295-301.
20. Zrihan-Licht S, Fu Y, Settleman J, Schinkmann K, Shaw L, et al. (2000) RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion. Oncogene 19: 1318-1328.
21. Behmoaram E, Bijian K, Jie S, Xu Y, Darnel A, et al. (2008) Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness. Am J Pathol 173: 1540-1550.
22. Sun CK, Ng KT, Sun BS, Ho JW, Lee TK, et al. (2007) The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence. Br J Cancer 97: 50-57.
23. Sun CK, Man K, Ng KT, Ho JW, Lim ZX, et al. (2008) Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation. Carcinogenesis 29: 2096-2105.
24. Sun CK, Ng KT, Lim ZX, Cheng Q, Lo CM, et al. (2011) Proline-Rich Tyrosine Kinase 2 (Pyk2) Promotes Cell Motility of Hepatocellular Carcinoma through Induction of Epithelial to Mesenchymal Transition. PLoS One 6: e18878.
25. Bagi CM, Christensen J, Cohen DP, Roberts WG, Wilkie D, et al. (2009) Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model. Cancer Biol Ther 8: 856-865.
26. Man K, Ng KT, Lee TK, Lo CM, Sun CK, et al. (2005) FTY720 attenuates hepatic ischemia-reperfusion injury in normal and cirrhotic livers. Am J Transplant 5: 40-49.
27. Man K, Shih KC, Ng KT, Xiao JW, Guo DY, et al. (2010) Molecular signature linked to acute phase injury and tumor invasiveness in small-for-size liver grafts. Ann Surg 251: 1154-1161.
28. Lee TK, Man K, Ho JW, Wang XH, Poon RT, et al. (2005) FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res 11: 8458-8466.
29. Janik P, Briand P, Hartmann NR, (1975) The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res 35: 3698-3704.
30. Man K, Ng KT, Xu A, Cheng Q, Lo CM, et al. (2010) Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res 16: 967-977.
31. Okusaka T, Ueno H, Ikeda M, (2004) [Chemotherapy for hepatocellular carcinoma]. Gan To Kagaku Ryoho 31: 2122-2128.
32. Gonzalez VM, Fuertes MA, Alonso C, Perez JM, (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59: 657-663.
33. Siddik ZH, (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279.
34. Liu LZ, Zhou XD, Qian G, Shi X, Fang J, et al. (2007) AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 67: 6325-6332.
35. Fujii T, Koshikawa K, Nomoto S, Okochi O, Kaneko T, et al. (2004) Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor. J Hepatol 41: 104-111.
36. Shen X, Xi G, Radhakrishnan Y, Clemmons DR, (2010) Recruitment of Pyk2 to SHPS-1 signaling complex is required for IGF-I-dependent mitogenic signaling in vascular smooth muscle cells. Cell Mol Life Sci.
37. Asechi H, Hatano E, Nitta T, Tada M, Iwaisako K, et al. (2010) Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int J Oncol 37: 89-96.
38. Lau CK, Yang ZF, Ho DW, Ng MN, Yeoh GC, et al. (2009) An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res 15: 3462-3471.
39. Luo G, Huang S, Xie X, Stockert E, Chen YT, et al. (2002) Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun 2: 11.
40. Kasuga C, Nakahara Y, Ueda S, Hawkins C, Taylor MD, et al. (2008) Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation. J Neurosurg Pediatr 1: 305-313.
41. Chou YY, Cheng AL, Hsu HC, (1997) Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. J Gastroenterol Hepatol 12: 569-575.
42. Minemura M, Tanimura H, Tabor E, (1999) Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. Int J Oncol 15: 559-563.
43. Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, et al. (2009) MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 78: 49-55.
44. Shiraga K, Sakaguchi K, Senoh T, Ohta T, Ogawa S, et al. (2001) Modulation of doxorubicin sensitivity by cyclosporine A in hepatocellular carcinoma cells and their doxorubicin-resistant sublines. J Gastroenterol Hepatol 16: 460-466.
45. Inamura K, Matsuzaki Y, Uematsu N, Honda A, Tanaka N, et al. (2005) Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-alpha in hepatocellular carcinoma cell lines. Biochim Biophys Acta 1745: 401-410.
46. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, et al. (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A 105: 18490-18495.
47. Langer R, Specht K, Becker K, Ewald P, Sarbia M, et al. (2004) [Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis]. Verh Dtsch Ges Pathol 88: 207-213.
48. Peng DJ, Wang J, Zhou JY, Wu GS, (2010) Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun 394: 600-605.
49. Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA, (2005) Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 65: 8423-8432.
50. Johnson-Holiday C, Singh R, Johnson EL, Grizzle WE, Lillard JW Jr, et al. (2011) CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J Surg Oncol 9: 46.